Alkermes plc
HealthcareNASDAQ:ALKS · NASDAQ Global Select
-$0.34 today
Vol 1.46M · Avg 2.34M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$1.6B of revenue converted into $152.7M of net income for the selected period. Gross margin is 86.6% and net margin is 9.8%, showing how much revenue survives after costs and taxes. EPS is $0.90, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5B -5.2% | $1.6B -6.4% | $1.7B +49.6% | $1.1B -5.3% | $1.2B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $196.5M -19.9% | $245.3M -3.0% | $253.0M +16.0% | $218.1M +10.5% | $197.3M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $1.3B -2.5% | $1.3B -7.0% | $1.4B +57.8% | $893.7M -8.5% | $976.4M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 86.7% +2.4pp | 84.2% -0.5pp | 84.8% +4.4pp | 80.4% -2.8pp | 83.2% | 9.8% | 28.9% | 38.3% |
| Research & Development | $324.0M +32.1% | $245.3M -9.4% | $270.8M -0.7% | $272.7M -6.3% | $290.9M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $701.5M +8.7% | $645.2M -6.5% | $689.8M +16.8% | $590.8M +7.5% | $549.6M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $1.0B +15.0% | $891.7M -10.5% | $996.2M +10.7% | $899.8M +2.4% | $878.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $27.2M -4.8% | $28.5M -61.9% | $74.9M -3.8% | $77.9M -1.0% | $78.7M | $374.2M | $1.2B | $631.8M |
| EBITDA | $330.9M -33.1% | $494.9M -4.7% | $519.5M +769.1% | $59.8M -66.3% | $177.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 22.4% -9.4pp | 31.8% +0.5pp | 31.2% +25.9pp | 5.4% -9.8pp | 15.1% | 5.6% | 46.3% | 42.0% |
| Operating Income | $254.0M -39.6% | $420.6M +1.6% | $414.1M +6901.1% | -$6.1M -106.2% | $97.7M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 17.2% -9.8pp | 27.0% +2.1pp | 24.9% +25.4pp | -0.5% -8.9pp | 8.3% | 16.6% | 24.1% | 22.0% |
| Interest Income | $45.3M +6.7% | $42.5M +37.6% | $30.9M +304.4% | $7.6M +216.8% | $2.4M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $12.3M -45.6% | $22.6M -2.0% | $23.0M +76.6% | $13.0M +16.2% | $11.2M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $37.5M +62.2% | $23.1M +212.5% | $7.4M +129.5% | -$25.0M -149.9% | -$10.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $291.4M -34.3% | $443.8M +5.3% | $421.5M +1454.1% | -$31.1M -135.5% | $87.7M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 19.7% -8.7pp | 28.5% +3.1pp | 25.3% +28.1pp | -2.8% -10.3pp | 7.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $49.8M -30.5% | $71.6M +173.3% | -$97.6M -4924.0% | $2.0M -82.1% | $11.3M | $1.3B | -$1.6B | $745.2M |
| Net Income | $241.7M -34.2% | $367.1M +3.2% | $355.8M +324.8% | -$158.3M -228.6% | -$48.2M | $4.9B | $4.8B | $4.7B |
| Net Margin | 16.4% -7.2pp | 23.6% +2.2pp | 21.4% +35.6pp | -14.2% -10.1pp | -4.1% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $1 -33.8% | $2 +3.7% | $2 +320.6% | -$1 -223.3% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $1 -34.1% | $2 +3.3% | $2 +316.5% | -$1 -223.3% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $164.7M -0.4% | $165.4M -0.5% | $166.2M +1.5% | $163.7M +1.7% | $160.9M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $168.7M -0.3% | $169.2M -0.3% | $169.7M +3.7% | $163.7M +1.7% | $160.9M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
$10.44B
TG Therapeutics, Inc.
NASDAQ:TGTX
$7.61B
Protagonist Therapeutics, Inc.
NASDAQ:PTGX
$7.08B
Kymera Therapeutics, Inc.
NASDAQ:KYMR
$7.03B
Vaxcyte, Inc.
NASDAQ:PCVX
$6.87B
Arcellx, Inc.
ACLX
$6.73B
PTC Therapeutics, Inc.
NASDAQ:PTCT
$6.22B
CRISPR Therapeutics AG
NASDAQ:CRSP
$4.81B
Akero Therapeutics, Inc.
AKRO
$4.50B
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
$3.64B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ALKS generate?
Alkermes plc (ALKS) reported $1.48B of revenue in fiscal 2025.
Is ALKS profitable?
Alkermes plc (ALKS) reported $241.66M of net income, with a net margin of 16.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.